Orally presented abstracts are marked with an asterisk ( * )
Abstract # 151 : Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay. ( A3 ) David V. Gold , PhD - Center for Molecular Medicine and Immunology/Garden State Cancer Center
Abstract # 152 : Malignant progression in intraductal papillary mucinous neoplasms of the pancreas: Results of 157 patients selected for radiographic surveillance. ( A4 ) Jennifer LaFemina , MD - Memorial Sloan-Kettering Cancer Center
Abstract # 153 : The impact of vascular reconstruction on early postoperative outcomes after pancreaticoduodenectomy: An analysis of the American College of Surgeons National Surgical Quality Improvement Program database. ( A5 ) Anthony W. Castleberry , MD - Duke University Medical Center
Abstract # LBA154^ : Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. ( A6 ) Riccardo Lencioni , MD - Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine
Abstract # 156 : Neoadjuvant chemoradiation versus surgery first for resectable pancreatic head adenocarcinoma: An economic and outcome analysis. ( A8 ) Daniel Erik Abbott , MD - University of Texas M. D. Anderson Cancer Center
Abstract # 157 : Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). ( A9 ) James C. Yao , MD - University of Texas M. D. Anderson Cancer Center
Abstract # 158 : SBRT as an alternative to RFA for the treatment of primary and metastatic liver tumors. ( A10 ) Erqi Liu , BS - University of Michigan
Abstract # 159 : Low 18f-fluorodeoxyglucose uptake on positron emission tomography as a prognostic factor for stage I and II pancreatic cancer. ( A11 ) Jose Mario Pimiento , MD - H. Lee Moffitt Cancer Center & Research Institute
Abstract # 160 : Diagnostic MicroRNA serum profile in pancreatic cancer. ( A12 ) Nicolai Aagaard Schultz , MD - Department of Surgical Gastroenterology and Transplantation, Rigshospitalet, University of Copenhagen
Abstract # 161 : Endoscopic ultrasound guided fine needle core biopsy versus aspiration for gastrointestinal mass lesions: A randomized trial. ( A13 ) Nam Q. Nguyen , Dr - Royal Adelaide Hospital
Abstract # 162 : Detection of resectable pancreatic cancer with SOMAmer proteomic technology. ( A14 ) Randall Brand , MD - University of Pittsburgh
Abstract # 163 : A population-based analysis of prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. ( A15 ) Alan D. Smith , MD - British Columbia Cancer Agency
Abstract # 164 : Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma. ( A16 ) David V. Gold , PhD - Center for Molecular Medicine and Immunology/Garden State Cancer Center
Abstract # 165 : S100A4 as a biomarker of resistance to gemcitabine: A secondary analysis of RTOG 9704. ( A17 ) Margaret A. Tempero , MD - University of California, San Francisco Comprehensive Cancer Center
Abstract # 166 : Biomarkers in pancreatic neuroendocrine tumors. ( A18 ) Angela Tatiana Alistar , MD - Mount Sinai School of Medicine
Abstract # 168 : Is laparoscopy still needed for staging "resectable" pancreatic cancer? ( A20 ) Peter Michael Santoro , MD - Christiana Care Health Services
Abstract # 169 : Use of endoscopic ultrasound to reduce the need for SpyGlass cholangioscopy and improve its diagnostic yield. ( A21 ) Nam Q. Nguyen , Dr - Royal Adelaide Hospital
Abstract # 170 : Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer. ( A22 ) Niranjan Awasthi , Ph.D. - University of Texas Southwestern Medical Center
Abstract # 171 : Association of high histone H3K4 trimethylation level and prognosis of patients with low-TNM-stage hepatocellular carcinoma. ( A23 ) Junyao Xu , MD,PhD - Sun Yat-sen memorial hospital, Sun Yat-sen University
Abstract # 172 : Blinded independent central response assessment using RECIST, mRECIST, and CHOI criteria in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). ( A24 ) Mohamed Bouattour , MD - Department of Oncology, Beaujon University Hospital
Abstract # 173 : Candidate biomarkers identified in the saliva of patients with pancreatic adenocarcinoma. ( A25 ) Jason B. Fleming , MD - University of Texas M. D. Anderson Cancer Center
Abstract # 174 : Utilization of hepatocellular carcinoma surveillance in the United States. ( A26 ) Samar Harris , MD - Department of Internal Medicine, University of Texas Southwestern Medical Center
Abstract # 175 : The association between metabolic syndrome and primary liver cancer: A meta-analysis. ( A27 ) Raxitkumar Jinjuvadia , MD, MPH - Wayne State University/Detroit Medical Center
Abstract # 176 : Value of preoperative biopsy and radiological assessment for the diagnosis of mixed hepatocellular cholangiocarcinoma (HCC-CC). ( A28 ) Mohamed Bouattour , MD - Department of Oncology, Beaujon University Hospital
Abstract # 177 : Revisiting the prognostic significance of positive peritoneal cytology in pancreatic cancer. ( A29 ) Kathryn T Chen , MD - Fox Chase Cancer Center
Abstract # 178 : The incidence and preoperative detection of nodal metastases in resected pancreatic neuroendocrine tumors. ( A30 ) James M. Lindberg , MD - University of Virginia
Abstract # 179 : Pancreatic neuroendocrine tumors: 20 years’ experience of 100 patients at a single center. ( A31 ) Satoshi Shiba , MD - National Cancer Center Hospital
Abstract # 180 : The metabolomic signature of pancreatic cancer in urine. ( A32 ) Vanessa Wylie Davis , MD - University of Alberta
Abstract # 181 : Relationship of STAT3-mediated treatment resistance on activated MAPK signaling in pancreatic cancer. ( A33 ) Nagaraj S Nagathihalli , Ph.D. - Vanderbilt University Medical Center
Abstract # 182 : Somatostatin receptor subtypes 1-5 gene expression in multiple sites in the same individual. ( A34 ) Michael Anthony Hall , MD, MSc. - Louisiana State University Health Sciences Center
Abstract # 183 : The role of NeuroD1 in the upregulation of SMYD3 by HBx. ( A35 ) Junyao Xu , MD,PhD - Sun Yat-sen memorial hospital, Sun Yat-sen University
Abstract # 184 : Epidemiology and survival of neuroendocrine tumors in Ontario: A 15-year population-based study. ( A36 ) Moises Cukier , MD - Sunnybrook Health Science Centre, University of Toronto
Abstract # 185 : Additional primary malignancies in patients with pancreatic cancer. ( A37 ) Shyam S. Allamaneni , MD - Roswell Park Cancer Institute
Abstract # 186 : Does a common vascular origin confer similar prognosis to malignant tumors of the liver? ( A38 ) Ryan T Groeschl , MD - Medical College of Wisconsin
Abstract # 187 : Baseline demographics of patients with neuroendocrine tumors presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database. ( A39 ) Michael A. Choti , MD, MBA - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Abstract # 188 : Use of the monoclonal antibody PAM4 to differentiate pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis and benign nonmucinous cysts of the pancreas. ( A40 ) Chanjuan Shi , M.D., Ph.D. - Vanderbilt University Medical Center Abstract # 189 : Variable expression of somatostatin receptor type 2 in metastatic midgut carcinoid. ( A41 ) Eric H Liu , M.D. - Vanderbilt University Medical Center
Abstract # 190 : Prevalence of risk factors among patients with hepatocellular carcinoma (HCC) and the general population in an employer group database. ( A42 ) QuynhChau Diem Doan , PhD,RPh,MS - Abbott Laboratories
Abstract # 191 : Factors associated with surgical resection for pancreatic and periampullary carcinomas in a cancer center in Mexico City. ( A43 ) Luis F. Onate-Ocana , M.D. - Instituto Nacional de Cancerologia
Abstract # 192 : Spanish registry and screening program for families at high risk of pancreatic adenocarcinoma. ( A44 ) Carmen Guillen-Ponce , MD, PhD - Ramón y Cajal University Hospital, IRYCIS
Abstract # 193 : Treating chronic hepatitis in Asian and Pacific island populations: A comparison of program costs according to current treatment guidelines. ( A45 ) Monica Cristina Robotin , MBBS, MBA - Cancer Council NSW
Abstract # 194 : Patients with liver cancer suitable for sorafenib evaluation registry (LIVER) in Poland. ( A46 ) Krzysztof Krzemieniecki , MD, PhD - Department of Oncology, Jagiellonian University
Abstract # 195 : Symptom changes that predict disease control by systemic chemotherapy in patients with advanced pancreatic cancer. ( B3 ) Akiko Kuwahara , MD - National Cancer Center Hospital East
Abstract # 196 : Methodology to screen and evaluate cost/survival of anticancer drugs in advanced/metastatic gastrointestinal cancers. ( B4 ) Helmy M. Guirgis , MD - University of California, Irvine
Abstract # 197 : Endobiliary jumbo forceps biopsy as a technique for diagnosing bile duct malignancies. ( B5 ) Michael H Hsu , MD, PhD - Rush University Medical Center
Abstract # 198 : Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). ( B6 ) Philip Agop Philip , MD, PhD, FRCP - Karmanos Cancer Institute, Wayne State University
Abstract # 199 : Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. ( B7 ) Cheryl L Attard , M.Sc. - Cornerstone Research Group Inc.
Abstract # 200 : MicroRNA analysis of fine-needle aspirates from pancreatic cancer. ( B8 ) Philip Agop Philip , MD, PhD, FRCP - Karmanos Cancer Institute, Wayne State University
Abstract # 201 : Transforming growth factor (TGF) β pathway and clinical outcome of pancreatic cancer. ( B9 ) Milind M. Javle , MD - University of Texas M. D. Anderson Cancer Center
Abstract # 202 : A novel xenograft model of gastrointestinal stromal tumor. ( B10 ) Jason Keith Sicklick , MD - University of California, San Diego
Abstract # 203 : Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205). ( B11 ) Melissa Janae Labonte , - University of Southern California Norris Comprehensive Cancer Center
Abstract # 204 : Inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) to increase radiosensitivity of human pancreatic cancer (PAC) cell lines proficient in homology-directed repair (HDR). ( B12 ) Maeve A Lowery , MD - Memorial Sloan-Kettering Cancer Center
Abstract # 205 : Serum adiponectin and overall survival in a prospective cohort of hepatocellular carcinoma patients. ( B13 ) Abby B. Siegel , MD, MS - Columbia University
Abstract # 206 : An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment. ( B14 ) Sarah B. Fisher , MD - Emory University, Winship Cancer Institute
Abstract # 207 : Significance of CEACAM6 expression in biliary tract carcinoma. ( B15 ) Flavio G. Rocha , MD - Virginia Mason Medical Center
Abstract # 208 : Acquired resistance to combination therapy with lapatinib and MEK 1/2 inhibitor GSK1120212 in an in vivo murine model of pancreatic cancer. ( B16 ) James M. Lindberg , MD - University of Virginia
Abstract # 209 : Staging of advanced hepatocellular carcinoma patients in the targeted therapy era. ( B17 ) Neeraj Nailesh Shah , MBBS - University of Texas M. D. Anderson Cancer Center
Abstract # 210 : Is the number of TACE treatments in HCC patients associated with improved survival? A SEER-Medicare population analysis. ( B18 ) Fadia T. Shaya , PhD, MPH - University of Maryland School of Pharmacy
Abstract # 211 : Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer. ( B19 ) Dung Thi Le , MD - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Abstract # 212 : Use of high-resolution fluorescence laparoscopy with fluorophore-conjugated tumor-specific antibodies for the detection of pancreatic cancer metastasis invisible with standard laparoscopy. ( B20 ) Cristiina A. Metildi , M.D. - University of California, San Diego
Abstract # 213 : A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. ( B21 ) Donald Anthony Richards , MD, PhD - US Oncology Research, LLC, The Woodlands, TX; Texas Oncology
Abstract # 214 : Comparative analysis of treatments, utilization, and survival benefit in HCC patients: A real-world analysis of SEER Medicare. ( B22 ) Fadia T. Shaya , PhD, MPH - University of Maryland School of Pharmacy
Abstract # 215 : Association of DNA repair inhibition and radiofrequency ablation in the treatment of xenografted colorectal cancer. ( B23 ) Flavien Devun , - Institut Curie
Abstract # 216 : Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition. ( B24 ) Chris Verslype , MD, PhD - Hepatology, University Hospitals Gasthuisberg
Abstract # 217 : Platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series. ( B25 ) Ben Tran , MBBS - Princess Margaret Hospital
Abstract # 218 : An integrated cross-species approach for the discovery of serum-based diagnostic biomarkers of PDAC using a genetically engineered murine model (GEMM). ( B26 ) Ferdinandos Skoulidis , MD, MRCP, PhD - University of Cambridge Department of Oncology, Addenbrooke's Hospital
Abstract # 219 : Can we identify cancer patients at high risk for cachexia? A prospective study in pancreatic cancer (PC). ( B27 ) David R. Fogelman , MD - University of Texas M. D. Anderson Cancer Center
Abstract # 220 : A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. ( B28 ) Richard S. Finn , MD - University of California, Los Angeles
Abstract # 221 : Association of KRAS G12D mutation with outcome in patients with pancreatic cancer after surgery. ( B29 ) Yo Mikayama , MD - Department of Gastrointestinal Surgery, Kanagawa Cancer Center
Abstract # 222 : An experimental model of FOLFOX-induced sinusoidal obstruction syndrome. ( B30 ) Stuart M. Robinson , - Institute of Cellular Medicine, Newcastle University
Abstract # 223 : Systemic inflammatory response to predict clinical outcome in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. ( B31 ) Soichiro Morinaga , MD, PhD - Department of Gastrointestinal Surgery, Kanagawa Cancer Center
Abstract # 224 : Possible role of autophagy inhibition in hypoxia-induced chemoresistance of pancreatic cancer cells. ( B32 ) Yoon Ho Ko , M.D. - Division of Oncology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, Catholic University
Abstract # 225 : A GEP-NEN analysis of incidence, ethic variation, and mortality using the SEER database. ( B33 ) Ben Lawrence , MBChB MSc - Yale University
Abstract # 226 : Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States. ( B34 ) Roman Casciano , M.S. - Analytica International
Abstract # 227 : Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study. ( B35 ) Allyson J. Ocean , MD - New York Presbyterian Hospital-Weill Cornell Medical College
Abstract # 228 : Comparative analysis of myeloid-derived suppressor cell (MDSC) subsets in patients with gastrointestinal (GI) malignancies. ( B36 ) Austin G. Duffy , MD - National Cancer Institute/National Institutes of Health
Abstract # 229 : Health plan budget impact of introducing everolimus for treatment of advanced progressive pancreatic neuroendocrine tumors in the United States. ( B37 ) Roman Casciano , M.S. - Analytica International
Abstract # 230 : Effect of 2G8, a TGFβR2 inhibitor, on TGF-β signaling and migration in an immunocompetent pancreatic cancer model. ( B38 ) Katherine Ostapoff , M.D. - University of Texas Southwestern Medical Center
Abstract # 231 : Paradoxical cross-talk between the Stat3 and MAPK pathways in CCL25-CCR9 mediated pancreatic cancer growth and proliferation. ( B39 ) Maithao N. Le , MD, PhD - City of Hope
Abstract # 232 : Use of global histone modifications to predict response to gemcitabine in patients with pancreatic cancer. ( B40 ) Takuo Watanabe , MD - Department of Gastrointestinal Surgery, Kanagawa Cancer Center Abstract # 233 : A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. ( B41 ) Michael Morse , M.D. - Duke University Medical Center
Abstract # 234 : Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo. ( B42 ) Katherine Ostapoff , M.D. - University of Texas Southwestern Medical Center
Abstract # 235 : Usefulness of circulating tumor cell detection for the diagnosis of malignant pancreatic head tumors: A pilot study. ( B43 ) Julien Coget , - Department of Pathology, Rouen University Hospital
Abstract # 236 : Sorafenib-induced loss of polarity of zymogen granules in pancreatic acinar cells. ( B44 ) Tatsuo Ito , MD - Department of Surgery, Kyoto University
Abstract # 237 : Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials. ( B45 ) James Signorovitch , PhD - Analysis Group, Inc.
Abstract # 238 : Selection, therapy, and outcome in an unselected population-based study of 604 patients with pancreatic cancer. ( B46 ) Jon Kroll Bjerregaard , MD - Department of Oncology, Odense University Hospital
Abstract # 239 : Validating the woodchuck model for studying antiangiogenic therapies for human hepatocellular carcinoma (HCC). ( C3 ) Kaunteya Reddy , MD - University at Buffalo
Abstract # 240 : Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer. ( C4 ) Junyao Xu , MD,PhD - Princess Margaret Hospital
Abstract # 241 : Phase I trial of gene-mediated cytotoxic immunotherapy combined with resection for pancreatic adenocarcinoma. ( C5 ) Lawrence Andrew Shirley , MD - The Ohio State University Medical Center
Abstract # 242 : Prognostication by multigene proliferative marker panel compared with ki-67 in small-intestinal NENs. ( C6 ) Ben Lawrence , MBChB MSc - Yale University
Abstract # 243 : Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on chemotherapy and antiangiogenic response in pancreatic cancer. ( C7 ) Katherine T Ostapoff , MD - University of Texas Southwestern
Abstract # 244 : Development of a tissue-equivalent human liver phantom for 90y-microsphere dosimetry studies and testing of other local ablation therapies. ( C8 ) Andrew S. Kennedy , MD, FACRO - Cancer Centers of North Carolina
Abstract # 245 : Novel small-molecule CRM-1 inhibitor for GI cancer therapy. ( C9 ) Asfar S. Azmi , PhD - Karmanos Cancer Institute
Abstract # 246 : Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? ( C10 ) Matias Emanuel Valsecchi , MD, MS - Department of Medical Oncology, Thomas Jefferson University Hospitals
Abstract # 247 : Looking for synergy or additivity between 188Re and sorafenib on hepatoma cell lines. ( C11 ) Marc Pracht , - Centre Eugène Marquis
Abstract # 248 : Efficacy of gemcitabine as second-line therapy after S-1 therapy failure in advanced pancreatic carcinoma. ( C12 ) Masaru Fukahori , - National Cancer Center Hospital
Abstract # 249 : Targeting hyaluronan (HA) in tumor stroma: Interim safety and translational evaluation of pegylated hyaluronidase (PEGPH20) in patients (pts) with advanced solid tumors—A focus on GI malignancies. ( C13 ) Jeffrey R. Infante , MD - The Sarah Cannon Cancer Center
Abstract # 250 : HER2 expression in patients with advanced pancreatic cancer: Preliminary results from a multifactorial biologic analysis. ( C14 ) Luca Faloppi , - Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche
Abstract # 251 : Resource utilization among neuroendocrine tumor patients in the United States. ( C15 ) Roman Casciano , M.S. - Analytica International
Abstract # 252 : Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. ( C16 ) Ryan Michael Thomas , MD - University of Texas M. D. Anderson Cancer Center
Abstract # 253 : Apricot-P: A randomized placebo controlled phase II study of COX-2 inhbitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas. ( C17 ) Manuel Modiano , MD - Arizona Clinical Research Center and Arizona Oncology
Abstract # 254 : Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib, and capecitabine for locally advanced pancreatic cancer (LAPC). ( C18 ) Heath Devin Skinner , MD, PhD - University of Texas M. D. Anderson Cancer Center
Abstract # 255 : Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805). ( C19 ) Chigusa Morizane , MD - National Cancer Center Hospital
Abstract # 256 : Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation? ( C20 ) Ryan T Groeschl , MD - Medical College of Wisconsin
Abstract # 257 : RTOG 0438: A phase I trial of highly conformal radiation therapy for patients with liver metastases. ( C21 ) Alan W. Katz , MD, MPH - University of Rochester
Abstract # 258 : Phase II trial of fixed-dose rate gemcitabine, bevacizumab, and concurrent 30 gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. ( C22 ) George Van Buren , MD - University of Pittsburgh
Abstract # 259 : Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). ( C23 ) Stephen Lam Chan , MD - State Key Laboratory in Oncology in South China, Department of Clinical Oncology, The Chinese University of Hong Kong
Abstract # 260 : Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). ( C24 ) Timothy J. Hobday , MD - Mayo Clinic
Abstract # 261 : Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT). ( C25 ) Allen Lee Cohn , MD - Rocky Mountain Cancer Center, LLP
Abstract # 262 : Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study. ( C26 ) Michael Bitzer , MD - Medical University Clinic, Eberhard-Karls-University
Abstract # 263 : A phase II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP-03). ( C27 ) Akio Saiura , MD - Cancer Institute Hospital
Abstract # 264 : The natural history and impact of adjuvant therapy on resected AJCC stage I-II lymph node-negative pancreatic cancer. ( C28 ) Shaun McKenzie , MD - University of Kentucky
Abstract # 266 : Neoadjuvant interferon-based chemoradiation for locally advanced pancreas cancer: A phase II pilot study. ( C30 ) Eric Hans Jensen , MD - University of Minnesota Medical Center
Abstract # 267 : Patterns of recurrence after resection of intrahepatic cholangiocarcinoma: Results from a multi-institutional cohort of 449 patients. ( C31 ) Ioannis Hatzaras , MD,MPH - Johns Hopkins University
Abstract # 268 : Cholangiocarcinoma: A joint cancer database analysis. ( C32 ) Yehuda Ethan Deutsch , MD - University of Miami Sylvester Comprehensive Cancer Center
Abstract # 269 : Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma. ( C33 ) Kyu-Hyoung Lim , MD - Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine
Abstract # 270 : Effect of treatment-related lymphopenia on survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. ( C34 ) Ani Sarkis Balmanoukian , MD - University of California, Irvine
Abstract # 271 : North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer. ( C35 ) George P. Kim , MD - North Central Cancer Treatment Group, Mayo Clinic
Abstract # 272 : Percutaneous irreversible electroporation (IRE) in the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC) to the liver: A retrospective analysis of the University of Miami experience. ( C36 ) Arturo Loaiza-Bonilla , MD - University of Miami Sylvester Comprehensive Cancer Center
Abstract # 273 : Evaluation of venous thromboembolism (VTE) risk among ambulatory patients with pancreatic cancer in a real-world setting. ( C37 ) Jay Lin , PhD - Novosys Health
Abstract # 274 : Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. ( C38 ) Tomohiro Yamaguchi , MD - National Cancer Center Hospital
Abstract # 275 : Advanced hepatocellular carcinoma (HCC) treated with sunitinib (Su) and transarterial chemoembolization (TACE): Phase II trial final report. ( C39 ) Renuka V. Iyer , MD - Roswell Park Cancer Institute
Abstract # 276 : Impact of bevacizumab on sinusoidal injury in patients receiving oxaliplatin-based chemotherapy and liver damage after massive hepatectomy in rats. ( C40 ) Mitsuo Shimada , MD, FACS. - Department of Surgery, The University of Tokushima
Abstract # 277 : Endoscopic or percutaneous biliary drainage for Klatskin tumors? A large retrospective study. ( C41 ) Thomas Walter , - Princess Margaret Hospital Abstract # 278 : Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use. ( C42 ) Robert C. G. Martin , MD, PhD - James Graham Brown Cancer Center, University of Louisville Abstract # 279 : Efficacy of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients. ( C43 ) Xudong Qu , - Zhongshan Hospital, Fudan University Abstract # 280 : Multimodality therapy for borderline resectable pancreatic cancer: A single-institution experience. ( C44 ) Jose Mario Pimiento , MD - H. Lee Moffitt Cancer Center & Research Institute Abstract # 281 : Use of probe-based confocal laser endomicroscopy (pCLE) in the diagnosis of cholangiocarcinoma. ( C45 ) John D Wysocki , MD - Tulane University School of Medicine
Abstract # 282 : Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): Sorafenib treatment and safety in U.S. patients with Child-Pugh B status. ( D4 ) Bilal Piperdi , MD - Montefiore Medical Center
Abstract # 283 : A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases (ILM) from colorectal cancer (CRC). ( D5 ) Deepa Magge , MD - University of Pittsburgh Medical Center
Abstract # 284 : Conditional survival probability of patients with resected pancreatic adenocarcinoma. ( D6 ) Mark Vikas Mishra , MD - Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University
Abstract # 285 : A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET). ( D7 ) Emily K. Bergsland , MD - University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
Abstract # 286 : Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC [uHCC] and of Its Treatment with Sorafenib): Differences in AE reporting across physician specialties. ( D8 ) Alan Paul Venook , MD - University of California, San Francisco
Abstract # 287 : Using the decline in CA19-9 after the start of chemotherapy to predict survival in patients with inoperable bile duct cancer. ( D9 ) Mie Grunnet , MD - Department of Oncology, Rigshopitalet
Abstract # 288 : Biliary tract cancer: A large institutional experience. ( D10 ) Mairead Geraldine McNamara , PhD - Princess Margaret Hospital
Abstract # 289 : Fear of cancer recurrence and quality of life among survivors of pancreatic and periampullary neoplasms. ( D11 ) Maria Q. B. Petzel , RD, CSO - University of Texas M. D. Anderson Cancer Center
Abstract # 290 : Radiofrequency ablation versus hepatic resection as an initial treatment for solitary small-sized hepatocellular carcinoma. ( D12 ) Katsunori Imai , M.D., Ph.D. - Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University
Abstract # 291 : Initial experience using percutaneous irreversible electroporation (IRE) in the treatment of locally advanced pancreatic adenocarcinoma (LAPC) with vascular encasement. ( D13 ) Peter Joel Hosein , MD - University of Miami Sylvester Comprehensive Cancer Center
Abstract # 292 : Associations between county-level general surgeon (GS) and gastroenterologist (GA) density and outcomes for hepatobiliary cancer (HBC). ( D14 ) Trevor C. Tsang , B.Sc, MM - British Columbia Cancer Agency
Abstract # 293 : Use of operability classifications to predict outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. ( D15 ) Ching-Wei David Tzeng , MD - University of Texas M. D. Anderson Cancer Center
Abstract # 294 : Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. ( D16 ) Linh My Alejandro , Pharm.D. - Memorial Sloan-Kettering Cancer Center
Abstract # 295 : Early experience with robotic radiosurgery for local control of liver metastasis. ( D17 ) Michael Kwiatt , MD - Cooper University Hospital
Abstract # 296 : A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer. ( D18 ) Jason Edward Faris , MD - Massachusetts General Hospital Cancer Center
Abstract # 297 : A single-institution survey of de novo secondary malignancies in patients occurring after orthotropic liver transplantation. ( D19 ) Quentin Gillebert , - Department of Oncology, Beaujon University Hospital
Abstract # 298 : Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC). ( D20 ) Ghassan K. Abou-Alfa , MD - Memorial Sloan-Kettering Cancer Center
Abstract # 299 : Pattern of failure after hepatic arterial concurrent chemoradiotherapy for locally advanced hepatocellular carcinoma. ( D21 ) Jinsil Seong , professor - Yonsei University Medical College
Abstract # 300 : Yttrium-90 microspheres (SIR) verses transarterial chemoembolization (TACE) in the treatment of inoperable metastatic neuroendocrine tumors (NETS). ( D22 ) Yuhsin V Wu , MD - Roswell Park Cancer Institute
Abstract # 301 : Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival. ( D23 ) Stephanie Krejcarek Childs , MD - Harvard Radiation Oncology Program
Abstract # 302 : Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): Sorafenib dosing and safety in U.S. patients. ( D24 ) Anthony B. El-Khoueiry , MD - University of Southern California Norris Comprehensive Cancer Center
Abstract # 303 : The introduction of bevacizumab for the treatment of metastatic colorectal cancer (CRC) in Ontario and its impact on hepatic metastectomy. ( D25 ) William Robert Leeper , MD - London Health Sciences Centre
Abstract # 304 : Margin status and neoadjuvant chemoradiation in patients with borderline resectable pancreatic cancer. ( D26 ) Pavlos Papavasiliou , MD - Fox Chase Cancer Center Abstract # 306 : Sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (HCC): Safety and efficacy in Child-Pugh (CP) class A and B patients. ( D28 ) Tiziana Pressiani , MD - Humanitas Cancer Center Abstract # 307 : Effect of chemoradiation-related lymphopenia on survival in patients with unresectable, locally advanced pancreatic adenocarcinoma. ( D29 ) Aaron Tyler Wild , BA - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Abstract # 308 : The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors. ( D30 ) Boris Naraev , MD, PhD - University of Iowa Hospitals and Clinics
Abstract # 309 : Impact of non-anticancer drugs on prognosis of pancreatic cancer (PaC) receiving chemotherapy. ( D31 ) Yousuke Nakai , M.D, Ph.D - University of Tokyo
Abstract # 310 : Is survival from resection of pancreatic adenocarcinoma with major arterial involvement any different than venous/minor arterial resection? ( D32 ) John T Miura , MD - Medical College of Wisconsin
Abstract # 311 : Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer. ( D33 ) Geoffrey Yuyat Ku , MD,MBA - Johns Hopkins Singapore International Medical Center
Abstract # 312 : Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study. ( D34 ) Thomas M. O'Dorisio , M.D. - University of Iowa Hospitals and Clinics
Abstract # 313 : FOLFIRINOX in locally advanced or metastatic pancreatic cancer. ( D35 ) Jason Edward Faris , MD - Massachusetts General Hospital Cancer Center
Abstract # 314 : Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial. ( D36 ) Robert R. McWilliams , MD - Mayo Clinic
Abstract # 315 : Percutaneous transhepatic biliary drainage (PTBD) in patients (pts) with advanced solid malignancies: Clinical outcomes and prognostic factors. ( D37 ) Marcela Alves Teixeira Crosara , MD - Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo
Abstract # 317 : Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): Second interim analysis of the Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib (GIDEON) study. ( D39 ) Jeff H. Geschwind , MD - The Johns Hopkins University School of Medicine
Abstract # 318 : Helical tomotherapy and concurrent gemcitabine-based chemotherapy for locally advanced pancreatic cancer. ( D40 ) Jinsil Seong , professor - Yonsei University Medical College
Abstract # 319 : Multiple utilities of portal vein embolization for patients with hepatocellular carcinoma. ( D41 ) Toru Beppu , M.D., Ph.D. - Department of Gastroenterological Surgery, Kumamoto University
Abstract # 320 : Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate. ( E4 ) Kiwamu Okita , MD, PhD - Shimonoseki Kohsei Hospital
Abstract # 321 : Margin distance as an independent predictor of survival after R0 resection for pancreatic adenocarcinoma. ( E5 ) George Van Buren , MD - University of Pittsburgh
Abstract # 322 : The role of fusion positron emission tomography/computed tomography (PET/CT) scan in patients with resectable pancreatic neoplasms. ( E6 ) Saqib Razzaque , MD - H. Lee Moffitt Cancer Center & Research Institute
Abstract # 323 : A phase I open-label, dose-escalation study of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. ( E7 ) Susan Joy Littman , MD - Kimmel Cancer Center of Thomas Jefferson University
Abstract # 324 : Dosimetic parameter predicting the hepatic complication after helical tomotherapy for patients with unresectable primary hepatocellular carcinoma. ( E8 ) HongSeok Jang , - Department of Radiation Oncology, The Catholic University of Korea
Abstract # 325 : Dose-escalated radiotherapy with helical tomotherapy to spine oligometastasis from intrahepatic malignancies. ( E9 ) Jinsil Seong , professor - Yonsei University Medical College
Abstract # 326 : The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: Implications for clinical management. ( E10 ) Maristella Bianconi , - Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche
Abstract # 327 : Neoadjuvant chemoradiation and intraoperative electron irradiation for locally unresectable/borderline resectable pancreas adenocarcinoma. ( E11 ) Jonathan Ben Ashman , MD, PhD - Mayo Clinic
Abstract # 328 : An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. ( E12 ) Weijing Sun , MD - Abramson Cancer Center, University of Pennsylvania
Abstract # 329 : Accelerated fraction radiotherapy with concomitant capecitabine as neoadjuvant therapy of borderline resectable pancreatic cancer. ( E13 ) Samhita Chakraborty , MD - University of Virgnia Health System
Abstract # 330 : Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). ( E14 ) Krishna Soujanya Gunturu , MD - Yale University School of Medicine
Abstract # 331 : Comparing the treatment outcomes between unresectable and recurrent cases receiving gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer: Pooled analysis of two prospective studies. ( E15 ) Takashi Sasaki , M.D., Ph.D. - University of Tokyo
Abstract # 332 : Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors. ( E16 ) Eric Steven Engelman , DO - University of Iowa Hospitals and Clinics
Abstract # 333 : Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy. ( E17 ) Xuezhong Yang , M.D. - Georgetown University Hospital Lombardi Cancer Center
Abstract # 334 : Demographic and prognostic factors in ampullary adenocarcinoma: A retrospective review of 74 sequential cases undergoing multidisciplinary management between 1997 and 2009. ( E18 ) Robert de Wilton Marsh , MD - Kellogg Cancer Center NorthShore University Health System
Abstract # 335 : Radiation in the management of pancreatic neuroendocrine tumors. ( E19 ) Bertram W Maidment , BS - University of Maryland School of Medicine
Abstract # 336 : Quality of life and acute radiation toxicity following hypofractionated stereotactic body radiation therapy with concurrent full-dose gemcitabine for unresectable pancreatic adenocarcinoma. ( E20 ) Marie Kate Gurka , M.D. - Georgetown University Hospital
Abstract # 337 : Toxicity study of gemcitabine, oxaliplatin, and bevacizumab followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy in patients with locally advanced pancreatic cancer. ( E21 ) Davendra Sohal , MD, MPH - Abramson Cancer Center, University of Pennsylvania
Abstract # 338 : Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer. ( E22 ) Thomas Walter , - Princess Margaret Hospital
Abstract # 339 : Whole-liver irradiation with hepatic arterial floxuridine/leucovorin/streptozotocin followed by hepatic arterial floxuridine/leucovorin and chemo-embolization with mitomycin C for patients with metastatic neuroendocrine tumors. ( E23 ) Mark Shilkrut , MD, PhD - Department of Radiation Oncology, University of Michigan Health System
Abstract # 340 : Incidence and natural history of bone metastases in neuroendocrine tumors. ( E24 ) Jennifer Keiser , MS - University of California, San Francisco
Abstract # 341 : Phase II trial of sorafenib and capecitabine for hepatocellular carcinoma in cirrhotic patients. ( E25 ) Yehuda Z. Patt , MD - University of New Mexico Cancer Center
Abstract # 342 : Adjuvant therapy in resected pancreatic cancer: A systematic review of literature with meta-analysis of randomized clinical trials. ( E26 ) Fabrizio Drudi , - Infermi Hospital
Abstract # 343 : 90y radioembolization for neuroendocrine cancers liver metastases provides sustained therapeutic effect with minimal toxicity. ( E27 ) Andrew S. Kennedy , MD, FACRO - Cancer Centers of North Carolina
Abstract # 344 : A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer. ( E28 ) Sun Jin Sym , - Department of Internal Medicine, Gachon University Gil Hospital
Abstract # 345 : A prospective randomized controlled trial comparing 4-weekly versus 3-weekly adjuvant chemotherapy with gemcitabine after curative resection of biliary tract cancer. ( E29 ) Shin Nakahira , - Department of Surgery, Kansai Rosai Hospital
Abstract # 346 : Developments of treatment of advanced intrahepatic cholangiocarcinoma: An analysis of systemic and local therapy modes in 57 patients. ( E30 ) Patrick Stuebs , MD - Otto-von-Guericke-University
Abstract # 347 : Stereotactic body radiotherapy (SBRT) in combination with surgery for primary and metastatic liver tumors. ( E31 ) Erik Lappinen , M.D. - Allegheny General Hospital
Abstract # 348 : Does age count in pancreatic resection? An Irish experience. ( E32 ) Louise Catherine Connell , BSc, MB, BCh, MRCPI - Department of Medical Oncology, Mercy University Hospital
Abstract # 349 : Correlation of biliary stenting with clinical outcome in patients with advanced pancreatic cancer treated with chemotherapy. ( E33 ) Luca Faloppi , - Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche
Abstract # 350 : Experience with sorafenib treatment of hepatocellular carcinoma (HCC) in patients in a Brazilian center. ( E34 ) Daniele Evaristo Alves , - Hospital do Servidor Público Estadual de São Paulo
Abstract # 351 : Does 18-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) predict survival in advanced pancreatic cancer? A single-institution experience. ( E35 ) Noman Ashraf , MD - H. Lee Moffitt Cancer Center & Research Institute
Abstract # 352 : Enhanced anti-tumor effect via combination of triptolide with 5- fluorouracil in pancreatic cancer cell lines. ( E36 ) Wei Wang , - Second Affiliated Hospital of Fujian Medical University
Abstract # 353 : Vitamin D deficiency in patients with pancreatic cancer. ( E37 ) Andrea Wang-Gillam , MD, PhD - Washington University in St. Louis
Abstract # 354 : Washington University experience with FOLFIRINOX in pancreatic cancer. ( E38 ) Parvin F. Peddi , MD - Washington University School of Medicine
Abstract # 355 : Liver resection for multifocal hepatocellular carcinoma. ( E39 ) Peter Tae Wan Kim , MD - Toronto General Hospital
Abstract # 356 : Rapamycin in patients with advanced hepatocellular carcinoma progressing on prior antiangiogenic therapy. ( E40 ) Mohamed Bouattour , MD - Department of Oncology, Beaujon University Hospital
Abstract # 357 : Transarterial infusion chemotherapy with cisplatin plus S-1 for treating hepatocellular carcinoma: Results of a phase I trial. ( E41 ) Tetsuji Terazawa , MD - National Cancer Center Hospital
bstract # 358 : The influence of surgical oncology fellowship programs in training hepatopancreatobiliary surgeons. ( E42 ) Rebecca Lynn Wiatrek , MD - City of Hope National Medical Center
Abstract # 359 : Retrospective analysis of treatment effects and prognostic factors associated with overall survival in patients with resected adenocarcinoma of the pancreas. ( E43 ) Dai Chu Nguyen Luu , MD - The Ohio State University Medical Center
Abstract # 360 : Combination of antiangiogenic therapy using the mTOR inhibitor RAD001 (everolimus) and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: Dose-finding study. ( E44 ) Mareile Joka , MD - Department of Surgery, University Clinic of Munich-Grosshadern
Abstract # 361 : Predicting survival in resected pancreatic cancer: A Canadian provincial experience. ( E45 ) Gillian Gresham , BSc - University of Ottawa
Abstract # 362 : Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors. ( F4 ) Tibor Gyökeres , - MAV Hospital and Central Medical Clinic
Abstract # 363 : The efficacy of capecitabine and temozolomide for the treatment of metastatic neuroendocrine tumors: Memorial Sloan-Kettering Cancer Center experience. ( F5 ) Alex Ganetsky , PharmD - Pharmacy Department, Memorial Sloan-Kettering Cancer Center
Abstract # 364 : Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. ( F6 ) Ishwaria Mohan Subbiah , MD, MS - Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas M. D. Anderson Cancer Center
Abstract # 365 : Comparison of the efficacy between the gemcitabine/cisplatin (GP) and capecitabine/cisplatin (XP) for the advanced biliary tract cancer: Retrospective analysis in a single institution. ( F7 ) Ji Eun Lee , - Seoul St. Mary's Hospital, The Catholic University of Korea
Abstract # 366 : Definitive radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer: A retrospective analysis. ( F8 ) Akira Nakamura , - Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University
Abstract # 367 : Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) for patients with advanced biliary carcinoma as a postoperative adjuvant chemotherapy. ( F9 ) Yuji Morine , MD. - Department of Surgery, The University of Tokushima
Abstract # 368 : Incidence and prediction of venous thromboembolism (VTE) in ambulatory patients (pts) with pancreas cancer receiving chemotherapy. ( F10 ) Ana Belen Ruperez Blanco , MD - Hospital General Univeristario Gregorio Marañon
Abstract # 369 : Identification of distinct phenotypes of locally advanced pancreas cancer. ( F11 ) MinYuen Teo , MB, MRCP - Department of Medical Oncology, Adelaide and Meath Hospital, incorporating the National Children's Hospital
Abstract # 370 : Patient-reported symptoms from advanced pancreatic cancer patients undergoing gemcitabine-based chemotherapy. ( F12 ) Xin Shelley Wang , MD, MPH - University of Texas M. D. Anderson Cancer Center
Abstract # 371 : The effect of total lymph nodes removed and the lymph node ratio on overall survival in resected pancreatic cancer. ( F13 ) Christina Wai , MD - Fox Chase Cancer Center
Abstract # 372 : Gemcitabine chemotherapy until symptomatic disease progression in advanced pancreatic cancer: A retrospective analysis. ( F14 ) Yuk Ting Ma , MBChB - The Cancer Centre, University Hospital Birmingham NHS Foundation Trust
Abstract # 373 : Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC). ( F15 ) Vinicius Ernani , MD - Jackson Memorial Hospital
Abstract # 374 : Sixty-six consecutive cases of neuroendocrine tumor treated with somatostatin analogues: A 20-year single-center experience. ( F16 ) Theodoros Savvoukidis , MD - Gastroenterology and Endocrinology, University Clinic of Goettingen
Abstract # 375 : Treatment and characteristics of patients treated for hepatocellular carcinoma (HCC) by physician types in the United States. ( F17 ) Brian S. Seal , PhD, RPh, MBA - Bayer HealthCare Pharmaceuticals
Abstract # 376 : Treatment of cholangiocarcinoma: Retrospetctive analysis of a single-center experience. ( F18 ) Ina Gaudig , - University of Medicine
Abstract # 377 : Evaluation of chemotherapy with cisplatin plus gemcitabine after failure of gemcitabine alone for unresectable or recurrent biliary tract cancer. ( F19 ) Ryo Kameda , MD - Division of Gastroenterology, Kanagawa Cancer Center Hospital
Abstract # 378 : Impact of a gastrointestinal multidisciplinary clinic on the quality of pancreatic cancer care delivery at a community cancer center. ( F20 ) Laurence E. McCahill , MD - Lacks Cancer Center
Abstract # 379 : Influence of intra-hepatic chemotherapy on survival of patients with colorectal liver metastasis treated with hepatic resection and systemic chemotherapy. ( F21 ) Mohammed Nawaf Kanaan , MD - McLaren Regional Medical Center, Michigan State University
Abstract # 380 : ABO blood group and survival in pancreatic cancer. ( F22 ) Christina Wai , MD - Fox Chase Cancer Center
Abstract # 381 : Phase II study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (NET). ( F23 ) Takuji Okusaka , MD, PhD - National Cancer Center Hospital
